The First Non-Steroidal Potential Therapy for Congenital Adrenal Hyperplasia

Congenital adrenal hyperplasia (CAH) is a rare endocrine disorder that results in the inability to produce the critical ‘stress’ hormone cortisol. Although CAH testing is a part of the newborn screening program, there are currently only steroidal FDA-approved therapies for CAH. CAH is typically treated with chronic, high-dose steroids often resulting in significant side effects. Spruce’s product candidate for CAH, Tildacerfont, is intended to correct hormone imbalance, giving patients a therapeutic option that treats their underlying disease and reduces their steroid burden.

Learn About CAH + View Our Research Pipeline +

Congenital Adrenal Hyperplasia Adult Clinical Trial

The CAHmelia 203 study is now open to screening and CAHmelia 204 will open shortly. To learn more, and see if you may qualify, go to or

Register Now